Bio-Strategy

Bio-Strategy, a subsidiary of DKSH Group, specializes in providing advanced laboratory solutions, focusing on digital PCR technology, which enhances precision in nucleic acid quantification for clinical diagnostics and scientific research. Bio-Strategy is a New Zealand-based company focused on delivering advanced laboratory solutions, particularly in the field of digital PCR technology. In November 2023, DKSH decided to fully acquire Bio-Strategy from Rangatira, which solidifies its position in the Asia Pacific region. The firm is headquartered in Auckland, New Zealand, and led by CEO John Chesterfield, who has a background in life sciences and technology ventures.

Bio-Strategy has completed a total of 2 deals, with the most recent deal dated 2023-11-02. Bio-Strategy, as part of the DKSH Group, specializes in providing advanced laboratory solutions, with a particular focus on digital PCR technology through its partnership with Stilla Technologies. Their core offerings include high-performance digital PCR systems designed to facilitate precise quantification of nucleic acids, thus addressing critical needs in clinical diagnostics, cancer research, drug development, and various scientific applications. These products are engineered for user-friendliness and versatility, setting new benchmarks in the field.

Bio-Strategy serves a diverse clientele, including research institutions, clinical laboratories, and universities across geographical markets such as New Zealand, Australia, and Southeast Asia, catering to sectors like healthcare, food and beverage, environmental testing, and forensic analysis. The revenue structure of Bio-Strategy is primarily driven by the sale of laboratory instruments and consumables, including specialized equipment and reagents essential for various scientific applications. Transactions typically occur through a B2B model, where the firm engages directly with research institutions and laboratories, offering both individual products and comprehensive solutions tailored to client needs. The business may also leverage subscription or partnership models for ongoing service and support, thereby fostering long-term relationships with clients.

Key product offerings include the Nio™ digital PCR system and an array of laboratory consumables marketed at competitive pricing, ensuring accessibility for both established laboratories and emerging research facilities. In November 2023, DKSH agreed to fully acquire Bio-Strategy, which will strengthen its position in the Asia Pacific region. This acquisition aims to support Bio-Strategy's future growth by facilitating the introduction of new products designed to meet growing market demands. As part of its expansion strategy, Bio-Strategy plans to enhance its market presence in Southeast Asia by 2024, capitalizing on the support from DKSH's established networks and resources.